Get the Stockscreener App
0.865
0.09%
0.0008
Pre-market:
.99
0.125
+14.45%
180 Life Sciences Corp stock is traded at $0.865, with a volume of 27,196.
It is up +0.09% in the last 24 hours and down -8.18% over the past month.
180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.
See More
Previous Close:
$0.8642
Open:
$0.905
24h Volume:
27,196
Relative Volume:
0.22
Market Cap:
$5.64M
Revenue:
-
Net Income/Loss:
$-3.12M
P/E Ratio:
-0.1797
EPS:
-4.8149
Net Cash Flow:
$-2.69M
1W Performance:
-9.90%
1M Performance:
-8.18%
6M Performance:
-53.74%
1Y Performance:
-40.75%
1-Day Range:
$0.86
$0.92
1-Week Range:
$0.86
$0.96
52-Week Range:
$0.6578
$17.75
180 Life Sciences Corp Stock (ATNF) Company Profile
Name
180 Life Sciences Corp
Sector
Industry
Phone
650-507-0669
Address
3000 EL CAMINO REAL, PALO ALTO
Compare ATNF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATNF
180 Life Sciences Corp
|
0.865 | 5.64M | 0 | -3.12M | -2.69M | -4.8149 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.54 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
511.92 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.76 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
257.51 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
180 Life Sciences Corp Stock (ATNF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-21 | Initiated | Maxim Group | Buy |
180 Life Sciences Corp Stock (ATNF) Latest News
180 Life Sciences Adopts 2025 Option Incentive Plan - TipRanks
Stocks to Watch: Jio Financial Services, Hero MotoCorp, Zydus Lifesciences, Abbott and more - CNBC TV18
Wealthcare Advisory Partners LLC Makes New Investment in Abrdn Life Sciences Investors (NYSE:HQL) - Defense World
Weiss Ratings Reiterates “Sell (E+)” Rating for 180 Life Sciences (NASDAQ:ATNF) - Defense World
908 Devices’ (MASS) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World
Equities Analysts Set Expectations for TLSI FY2026 Earnings - Defense World
Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace
Anavex Life Sciences Corp. (NASDAQ:AVXL) Stock Holdings Lessened by BNP Paribas Financial Markets - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings - Defense World
Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by BNP Paribas Financial Markets - Defense World
180 Life Sciences’ (ATNF) Sell (E+) Rating Reaffirmed at Weiss Ratings - Defense World
Why Intuit Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Maravai Sustainability Report: 10x Manufacturing Expansion Plus Major Green Energy Milestones - Stock Titan
Tower Research Capital LLC TRC Buys 1,708 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Brings Alzheimer's and Parkinson's Drug Updates to Prestigious Wainwright Healthcare Conferences - Stock Titan
180 Life Sciences’ (ATNF) Sell (E+) Rating Reiterated at Weiss Ratings - Defense World
Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan
180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program - Barchart.com
ATNF’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
Breakthrough Diabetes Treatment: New Neuromodulation Device Eliminates Need for Insulin Injections - Stock Titan
180 Life Sciences Gets Notice of Allowance for Method to Prevent POCD - marketscreener.com
MAGIC Nashville Showcases Premier Southeastern Women's Fashion Trends and Innovations - Digital Journal
180 Life Sciences (ATNF) Secures Patent Approval for POCD Treatm - GuruFocus
180 Life Sciences nears patent for post-surgery cognitive aid By Investing.com - Investing.com India
180 Life Sciences nears patent for post-surgery cognitive aid - Investing.com
180 Life Sciences Corp. Announces Notice of Allowance for U.S. P - GuruFocus
180 Life Sciences Corp. Announces Notice of Allowance for U.S. Patent Covering Novel Method to Prevent or Reduce Post-Operative Cognitive Dysfunction | ATNF Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Patent Breakthrough: 180 Life Sciences Develops First Treatment to Prevent Post-Surgery Cognitive Decline in Elderly - Stock Titan
Budapest Draws in Summer Visitors for an Adventure Along the Danube - Digital Journal
180 Life Sciences (ATNF) Restructures Capital with Share Repurch - GuruFocus
180 Life Sciences to buy back shares, simplifies capital structure By Investing.com - Investing.com India
180 Life Sciences Settles Disputes with Elray Resources - TipRanks
180 Life Sciences Corp. Announces Share Repurchase | ATNF Stock News - GuruFocus
180 Life Sciences to buy back shares, simplifies capital structure - Investing.com Australia
180 Life Sciences Launches Massive 23% Share Reduction Plan: Key Details of $1M Strategic Buyback - Stock Titan
180 Life Sciences Corp. (NASDAQ:ATNF) Sees Large Increase in Short Interest - Defense World
Short Interest in Adlai Nortye Ltd. (NASDAQ:ANL) Decreases By 51.6% - Defense World
Q4 Results This Week: BPCL, Varun Beverages, Vedanta, SBI, Trent Among 180+ Companies To Declare Earnings - NDTV Profit
180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector - ACCESS Newswire
180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules - ACCESS Newswire
180 Life Sciences’ (ATNF) “Sell (E+)” Rating Reiterated at Weiss Ratings - Defense World
Dupuytren's Disease Market Valuation Expected To Reach $8.54 Billion By 2029 Growing At A Rate Of 9% As Rev... - WhaTech
Alliancebernstein L.P. Has $1.12 Million Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Geode Capital Management LLC Sells 247,336 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) - Defense World
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings - Yahoo Finance
Arrowstreet Capital Limited Partnership Has $312,000 Position in Integra LifeSciences Holdings Co. (NASDAQ:IART) - Defense World
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
Elray Resources Announces Strategic Sale of Crypto iGaming Technology - ADVFN
Pre-market Movers: VERO, WORX, QLGN, VINC... - RTTNews
180 Life Sciences Corp Stock (ATNF) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.27%
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):